medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2021-35-23-28medalphabet-2355Research ArticleСТОМАТОЛОГИЯDENTISTRYПостинфекционный синдром раздраженного кишечника: время ренессанса?Post-infectious irritable bowel syndrome: renaissance time?https://orcid.org/0000-0001-9370-4768ГаусО. В.GausO. V.

Гаус Ольга Владимировна - кандидат медицинских наук, доцент кафедры факультетской терапии и гастроэнтерологии, Scopus ID: 56598554900.

Омск

Gaus Olga V. - PhD Med, associate professor at Dept of Faculty Therapy and Gastroenterology. Scopus ID: 56598554900.

Omsk

gaus_olga@bk.ruhttps://orcid.org/0000-0002-6581-7017ЛивзанМ. А.LivzanM. A.

Ливзан Мария Анатольевна - доктор медицинских наук, профессор, ректор, зав. кафедрой факультетской терапии и гастроэнтерологии, Scopus ID: 24341682600.

Омск

Livzan Maria A. - DM Sci (habil.), professor, rector, head of Dept of Faculty Therapy and Gastroenterology. Scopus ID: 24341682600.

Omsk

mlivzan@yandex.ruhttps://orcid.org/0000-0001-5245-7190ГавриленкоД. А.GavrilenkoD. A.

Гавриленко Дарья Александровна - студентка V курса лечебного факультета.

Омск

Gavrilenko Darya A. - 5th year student of the Faculty of Medicine.

Omsk

ФГБОУ ВО Омский государственный медицинский университет Минздрава РоссииРоссияOmsk State Medical UniversityRussian Federation202118122021035Практическая гастроэнтерология (3)2328Copyright © Гаус О.В., Ливзан М.А., Гавриленко Д.А., 20212021Гаус О.В., Ливзан М.А., Гавриленко Д.А.Gaus O.V., Livzan M.A., Gavrilenko D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2355

Постинфекционный синдром раздраженного кишечника (ПИ-СРК) представляет собой отдельный фенотип заболевания, при котором возникновение гастроинтестинальных симптомов, соответствующих диагностическим критериям СРК, находится в прямой хронологической связи с эпизодом острой кишечной инфекции. Длительное время ПИ-СРК рассматривался как исход паразитарной, протозойной или бактериальной инфекции. По мере глобального распространения новой коронавирусной инфекции COVID-19 стала очевидной тенденция к росту числа новых случаев СРК в популяции, что наводит на мысль о ренессансе проблемы ПИ-СРК и заставляет клиницистов по-новому взглянуть на нее. В настоящей публикации обобщены и представлены современные сведения о возможных механизмах развития ПИ-СРК, в том числе у лиц, перенесших COVID-19.

Postinfectious irritable bowel syndrome (PI–IBS) is a distinct phenotype of the disease. The occurrence of gastrointestinal symptoms in PI–IBS is in direct chronological connection with an episode of acute intestinal infection. Previously the problem was considered as the outcome of parasitic, protozoal or bacterial infection. The global spread of a novel coronavirus infection (COVID-19) and increase in the number of new cases of IBS in the population suggests a renaissance of PI–IBS and makes us look at this problem again. This article summarizes and presents modern information on the possible mechanisms of development of PI–IBS, including in persons who have undergone COVID-19.

функциональные гастроинтестинальные расстройствапостинфекционный синдром раздраженного кишечникаострая кишечная инфекцияCOVID-19модуляция микробиотыповышенная кишечная проницаемостьметаболизм нейротрансмиттеровfunctional gastrointestinal disorderspost-infectious irritable bowel syndromeacute intestinal infectionCOVID-19microbiota modulationincreased intestinal permeabilityneurotransmitter metabolismReferencesИвашкин В. Т., Шелыгин Ю. А., Баранская Е. К., Белоусова Е. А., Бениашвили А. Г., Васильев С. В. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации, Ассоциации колопроктологов России по диагностике и лечению больных с синдромом раздраженного кишечника. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017; 27 (5): 76–93. https://doi.org/10.22416/1382–4376–2017–27–5–76–93Ivashkin V. T., Shelygin Yu.A., Baranskaya Yu.K., Belousova E. A., Beniashvili A. G., Vasilyev S. V. et al. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Ross z gastroenterol. Gepatol, koloproktol. 2017; 27 (5): 76–93. https://doi.org/10.22416/1382–4376–2017–27–5–76–93 2.Flacco M. E., Manzoli L., De Giorgio R., Gasbarrini A., Cicchetti A., Bravi F. et al. Costs of irritable bowel syndrome in European countries with universal healthcare cover-age: a meta-analysis. Eur. Rev. Med. Pharmacol. 2019; 23 (7): 2986–3000. https://doi.org/10.26355/eurrev_201904_17580Flacco M. E., Manzoli L., De Giorgio R., Gasbarrini A., Cicchetti A., Bravi F. et al. Costs of irritable bowel syndrome in European countries with universal healthcare cover-age: a meta-analysis. Eur. Rev. Med. Pharmacol. 2019; 23 (7): 2986–3000. https://doi.org/10.26355/eurrev_201904_17580Peery A. F., Crockett S. D., Murphy C. C., Lund J. L., Dellon E. S., Williams J. L., et al. Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018. Gastroenterology. 2019; 156 (1): 254–272.e11. https://doi.org/10.1053/j.gastro.2018.08.063Peery A. F., Crockett S. D., Murphy C. C., Lund J. L., Dellon E. S., Williams J. L., et al. Bur-den and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018. Gastroenterology. 2019; 156 (1): 254–272.e11. https://doi.org/10.1053/j.gastro.2018.08.063Barbara G., Grover M., Bercik P., Corsetti M., Ghoshal U. C., Ohman L., Rajilić-Stojanović M. Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome. Gastroenterology. 2019; 156 (1): 46–58.e7. https://doi.org/10.1053/j.gastro.2018.07.011Barbara G., Grover M., Bercik P., Corsetti M., Ghoshal U. C., Ohman L., Rajilić-Stojanović M. Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome. Gastroenterology. 2019; 156 (1): 46–58.e7. https://doi.org/10.1053/j.gastro.2018.07.011Chaudhary N. A., Truelove S. C. The irritable colon syndrome. A study of the clinical fea-tures, predisposing causes, and prognosis in 130 cases. Q. J. Med. 1962; (31): 307–322.Chaudhary N. A., Truelove S. C. The irritable colon syndrome. A study of the clinical fea-tures, predisposing causes, and prognosis in 130 cases. Q. J. Med. 1962; (31): 307–322.Thabane M., Marshall J. K. Post-infectious irritable bowel syndrome. World. J. Gastro-enterol. 2009; 15 (29): 3591–6. https://doi.org/10.3748/wjg.15.3591Thabane M., Marshall J. K. Post-infectious irritable bowel syndrome. World. J. Gastro-enterol. 2009; 15 (29): 3591–6. https://doi.org/10.3748/wjg.15.3591Klem F., Wadhwa A., Prokop L. J., Sundt W. J., Farrugia G., Camilleri M. et al. Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis. Gastroenterology. 2017; 152 (5): 1042–1054.e1. https://doi.org/10.1053/j.gastro.2016.12.039Klem F., Wadhwa A., Prokop L. J., Sundt W. J., Farrugia G., Camilleri M. et al. Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis. Gastroenterology. 2017; 152 (5): 1042–1054.e1. https://doi.org/10.1053/j.gastro.2016.12.039Marshall J. K., Thabane M., Garg A. X., Clark W. F., Salvadori M., Collins S. M. Walkerton Health Study Investigators. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology. 2006; 131 (2): 445–50; quiz 660. https://doi.org/10.1053/j.gastro.2006.05.053Marshall J. K., Thabane M., Garg A. X., Clark W. F., Salvadori M., Collins S. M. Walkerton Health Study Investigators. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology. 2006; 131 (2): 445–50; quiz 660. https://doi.org/10.1053/j.gastro.2006.05.053Neal K. R., Hebden J., Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ. 1997; 314 (7083): 779–82. https://doi.org/10.1136/bmj.314.7083.779Neal K. R., Hebden J., Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ. 1997; 314 (7083): 779–82. https://doi.org/10.1136/bmj.314.7083.779Cremon C., Stanghellini V., Pallotti F., Fogacci E., Bellacosa L., Morselli-Labate A.M. et al. Salmonella gastroenteritis during childhood is a risk factor for irritable bowel syndrome in adulthood. Gastroenterology. 2014; 147 (1): 69–77. https://doi.org/10.1053/j.gastro.2014.03.013Cremon C., Stanghellini V., Pallotti F., Fogacci E., Bellacosa L., Morselli-Labate A.M. et al. Salmonella gastroenteritis during childhood is a risk factor for irritable bowel syndrome in adulthood. Gastroenterology. 2014; 147 (1): 69–77. https://doi.org/10.1053/j.gastro.2014.03.013Nielsen H. L., Engberg J., Ejlertsen T., Nielsen H. Psychometric scores and persistence of irritable bowel after Campylobacter concisus infection. Scand J Gastroenterol. 2014; 49 (5): 545–51. https://doi.org/10.3109/00365521.2014.886718Nielsen H. L., Engberg J., Ejlertsen T., Nielsen H. Psychometric scores and persistence of irritable bowel after Campylobacter concisus infection. Scand J Gastroenterol. 2014; 49 (5): 545–51. https://doi.org/10.3109/00365521.2014.886718Ruigomez A., García Rodriguez L. A., Panes J. Risk of irritable bowel syndrome after an episode of bacterial gastroenteritis in general practice: influence of comorbidities. Clin Gastroenterol Hepatol. 2007; 5 (4): 465–9. https://doi.org/10.1016/j.cgh.2007.02.008Ruigomez A., García Rodriguez L. A., Panes J. Risk of irritable bowel syndrome after an episode of bacterial gastroenteritis in general practice: influence of comorbidities. Clin Gastroenterol Hepatol. 2007; 5 (4): 465–9. https://doi.org/10.1016/j.cgh.2007.02.008Thabane M., Simunovic M., Akhtar-Danesh N., Garg A. X., Clark W. F., Collins S. M. et al. An outbreak of acute bacterial gastroenteritis is associated with an increased incidence of irritable bowel syndrome in children. Am J Gastroenterol. 2010; 105 (4): 933–9. https://doi.org/10.1038/ajg.2010.74Thabane M., Simunovic M., Akhtar-Danesh N., Garg A. X., Clark W. F., Collins S. M. et al. An outbreak of acute bacterial gastroenteritis is associated with an increased incidence of irritable bowel syndrome in children. Am J Gastroenterol. 2010; 105 (4): 933–9. https://doi.org/10.1038/ajg.2010.74Koh S. J., Lee D. H., Lee S. H., Park Y. S., Hwang J. H., Kim J. W. et al. Incidence and risk factors of irritable bowel syndrome in community subjects with cultureproven bacterial gastroenteritis. Korean J. Gastroenterol. 2012; 60 (1): 13–8. https://doi.org/10.4166/kjg.2012.60.1.13Koh S. J., Lee D. H., Lee S. H., Park Y. S., Hwang J. H., Kim J. W. et al. Incidence and risk factors of irritable bowel syndrome in community subjects with cultureproven bacterial gastroenteritis. Korean J. Gastroenterol. 2012; 60 (1): 13–8. https://doi.org/10.4166/kjg.2012.60.1.13Törnblom H., Holmvall P., Svenungsson B., Lindberg G. Gastrointestinal symptoms after infectious diarrhea: a five-year follow-up in a Swedish cohort of adults. Clin. Gastroenterol. Hepatol. 2007 Apr; 5 (4): 461–4. https://doi.org/10.1016/j.cgh.2007.01.007Törnblom H., Holmvall P., Svenungsson B., Lindberg G. Gastrointestinal symptoms after infectious diarrhea: a five-year follow-up in a Swedish cohort of adults. Clin. Gastroenterol. Hepatol. 2007 Apr; 5 (4): 461–4. https://doi.org/10.1016/j.cgh.2007.01.007Ruigomez A., Garcia Rodriguez L. A., Panes J. Risk of irritable bowel syndrome after an episode of bacterial gastroenteritis in general practice: influence of comorbidities. Clin Gastroenterol Hepatol. 2007; 5 (4): 465–469. https://doi.org/10.1016/j.cgh.2007.02.008Ruigomez A., Garcia Rodriguez L. A., Panes J. Risk of irritable bowel syndrome after an episode of bacterial gastroenteritis in general practice: influence of comorbidities. Clin Gastroenterol Hepatol. 2007; 5 (4): 465–469. https://doi.org/10.1016/j.cgh.2007.02.008Pitzurra R. Fried M., Rogler G., Rammert C., Tschopp A., Hatz C. et al. irritable bowel syndrome among a cohort of European travelers to resource-limited destinations.Pitzurra R. Fried M., Rogler G., Rammert C., Tschopp A., Hatz C. et al. irritable bowel syndrome among a cohort of European travelers to resource-limited destinations. J. Travel. Med. 2011; 18 (4): 250–6. https://doi.org/10.1111/j.1708–8305.2011.00529.xJ. Travel. Med. 2011; 18 (4): 250–6. https://doi.org/10.1111/j.1708–8305.2011.00529.xThabane M., Simunovic M., Akhtar-Danesh N., Garg A. X., Clark W. F., Collins S. M. et al. An outbreak of acute bacterial gastroenteritis is associated with an increased incidence of irritable bowel syndrome in children. Am J Gastroenterol. 2010 Apr; 105 (4): 933–9. https://doi.org/10.1038/ajg.2010.74Thabane M., Simunovic M., Akhtar-Danesh N., Garg A. X., Clark W. F., Collins S. M. et al. An outbreak of acute bacterial gastroenteritis is associated with an increased incidence of irritable bowel syndrome in children. Am J Gastroenterol. 2010 Apr; 105 (4): 933–9. https://doi.org/10.1038/ajg.2010.74Nielsen H. L., Engberg J., Ejlertsen T., Nielsen H. Psychometric scores and persistence of irritable bowel after Campylobacter concisus infection. Scand J Gastroenterol. 2014; 49 (5): 545–51. https://doi.org/10.3109/00365521.2014.886718Nielsen H. L., Engberg J., Ejlertsen T., Nielsen H. Psychometric scores and persistence of irritable bowel after Campylobacter concisus infection. Scand J Gastroenterol. 2014; 49 (5): 545–51. https://doi.org/10.3109/00365521.2014.886718Zhang Y., Li L., Guo C., Mu D., Feng B., Zuo X., et al. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: A meta-analysis. BMC Gastroenterol. 2016; 16: 62.Zhang Y., Li L., Guo C., Mu D., Feng B., Zuo X., et al. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: A meta-analysis. BMC Gastroenterol. 2016; 16: 62.Pinto-Sanchez M.I., Smecuol E. C., Temprano M. P., Sugai E., Gonzalez A., Moreno M. L. et al. Bifidobacterium infantis NLS super strain reduces the expression of alpha-Defensin-5, a marker of innate immunity, in the mucosa of active celiac disease patients. J. Clin. Gastroenterol. 2017; 51: 814–817. https://doi.org/10.1097/MCG.0000000000000687Pinto-Sanchez M.I., Smecuol E. C., Temprano M. P., Sugai E., Gonzalez A., Moreno M. L. et al. Bifidobacterium infantis NLS super strain reduces the expression of alpha-Defensin-5, a marker of innate immunity, in the mucosa of active celiac disease patients. J. Clin. Gastroenterol. 2017; 51: 814–817. https://doi.org/10.1097/MCG.0000000000000687Quek S. X.Z., Loo E. X.L., Demutska A., Chua C. E., Kew G. S., Wong S. et al. Impact of the coronavirus disease 2019 pandemic on irritable bowel syndrome. J Gastroenterol Hepatol. 2021; 36 (8): 2187–2197. https://doi.org/10.1111/jgh.15466Quek S. X.Z., Loo E. X.L., Demutska A., Chua C. E., Kew G. S., Wong S. et al. Impact of the coronavirus disease 2019 pandemic on irritable bowel syndrome. J Gastroenterol Hepatol. 2021; 36 (8): 2187–2197. https://doi.org/10.1111/jgh.15466Effenberger M., Grabherr F. Mayr L., Schwaerzler J., Nairz M., Seifert M. et al. Faecal calprotectin indicates intestinal inflammation in COVID-19. Gut. 2020; 69 (8): 1543–1544. https://doi.org/10.1136/gutjnl-2020–321388Effenberger M., Grabherr F. Mayr L., Schwaerzler J., Nairz M., Seifert M. et al. Faecal calprotectin indicates intestinal inflammation in COVID-19. Gut. 2020; 69 (8): 1543–1544. https://doi.org/10.1136/gutjnl-2020–321388Han C., Duan C., Zhang S., Spiegel B., Shi H., Wang W. et al. Digestive Symptoms in COVID-19 Patients with Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes. Am J Gastroenterol. 2020; 115 (6): 916–923. https://doi.org/10.14309/ajg.0000000000000664Han C., Duan C., Zhang S., Spiegel B., Shi H., Wang W. et al. Digestive Symptoms in COVID-19 Patients with Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes. Am J Gastroenterol. 2020; 115 (6): 916–923. https://doi.org/10.14309/ajg.0000000000000664Spiller R. Significance of Postinfectious Irritable Bowel Syndrome? Gastroenterology. 2018: S 0016–5085 (18) 35282-X. https://doi.org/10.1053/j.gastro.2018.11.034Spiller R. Significance of Postinfectious Irritable Bowel Syndrome? Gastroenterology. 2018: S 0016–5085 (18) 35282-X. https://doi.org/10.1053/j.gastro.2018.11.034Yang W., Cong Y. Gut microbiota-derived metabolites in the regulation of host immune responses and immune-related inflammatory diseases. Cell. Mol. Immunol. 2021; 18 (4): 866–877. https://doi.org/10.1038/s41423–021–00661–428 Медицинский алфавит № 35 / 2021. Практическая гастроэнтерология (3)Yang W., Cong Y. Gut microbiota-derived metabolites in the regulation of host immune responses and immune-related inflammatory diseases. Cell. Mol. Immunol. 2021; 18 (4): 866–877. https://doi.org/10.1038/s41423–021–00661–428Azad M. A.K., Sarker M., Wan D. Immunomodulatory Effects of Probiotics on Cytokine Profiles. Biomed. Res. Int. 2018; 2018: 8063647. https://doi.org/10.1155/2018/8063647Azad M. A.K., Sarker M., Wan D. Immunomodulatory Effects of Probiotics on Cytokine Profiles. Biomed. Res. Int. 2018; 2018: 8063647. https://doi.org/10.1155/2018/8063647Faith J. J., Guruge J. L., Charbonneau M., Subramanian S., Seedorf H., Goodman A. L. et al. The long-term stability of the human gut microbiota. Science. 2013; 341 (6141): 1237439. https://doi.org/10.1126/science.1237439Faith J. J., Guruge J. L., Charbonneau M., Subramanian S., Seedorf H., Goodman A. L. et al. The long-term stability of the human gut microbiota. Science. 2013; 341 (6141): 1237439. https://doi.org/10.1126/science.1237439Dicksved J., Ellström P., Engstrand L., Rautelin H. Susceptibility to Campylobacter infection is associated with the species composition of the human fecal microbiota. mBio. 2014; 5 (5): e01212–14. https://doi.org/10.1128/mBio.01212–14Dicksved J., Ellström P., Engstrand L., Rautelin H. Susceptibility to Campylobacter infection is associated with the species composition of the human fecal microbiota. mBio. 2014; 5 (5): e01212–14. https://doi.org/10.1128/mBio.01212–14Chong P. P., Chin V. K., Looi C. Y., Wong W. F., Madhavan P., Yong V. C. The Microbiome and Irritable Bowel Syndrome – A Review on the Pathophysiology, Current Research and Future Therapy. Front. Microbiol. 2019; 10: 1136. https://doi.org/10.3389/fmicb.2019.01136Chong P. P., Chin V. K., Looi C. Y., Wong W. F., Madhavan P., Yong V. C. The Microbiome and Irritable Bowel Syndrome – A Review on the Pathophysiology, Current Research and Future Therapy. Front. Microbiol. 2019; 10: 1136. https://doi.org/10.3389/fmicb.2019.01136Carroll I. M., Ringel-Kulka T., Siddle J. P., Ringel Y. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 2012; 24 (6): 521–30, e248. https://doi.org/10.1111/j.1365–2982.2012.01891.xCarroll I. M., Ringel-Kulka T., Siddle J. P., Ringel Y. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 2012; 24 (6): 521–30, e248. https://doi.org/10.1111/j.1365–2982.2012.01891.xZuo T. Zhang F., Lui G. C.Y., Yeoh Y. K., Li A. Y.L., Zhan H. et al. Alterations in Gut Microbi-ota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology. 2020; 159 (3): 944–955.e8. https://doi.org/10.1053/j.gastro.2020.05.048Zuo T. Zhang F., Lui G. C.Y., Yeoh Y. K., Li A. Y.L., Zhan H. et al. Alterations in Gut Microbi-ota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology. 2020; 159 (3): 944–955.e8. https://doi.org/10.1053/j.gastro.2020.05.048Schmulson M., Davalos M. F., Berumen J. Beware: Gastrointestinal symptoms can be a manifestation of COVID-19. Rev. Gastroenterol. Mex. (Engl Ed). 2020; 85 (3): 282–287. https://doi.org/10.1016/j.rgmx.2020.04.001Schmulson M., Davalos M. F., Berumen J. Beware: Gastrointestinal symptoms can be a manifestation of COVID-19. Rev. Gastroenterol. Mex. (Engl Ed). 2020; 85 (3): 282–287. https://doi.org/10.1016/j.rgmx.2020.04.001Marshall J. K., Thabane M., Garg A. X., Clark W., Meddings J., Collins S. M.; WEL Investigators. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment. Pharmacol. Ther. 2004; 20 (11–12): 1317–22. https://doi.org/10.1111/j.1365–2036.2004.02284.xMarshall J. K., Thabane M., Garg A. X., Clark W., Meddings J., Collins S. M.; WEL Investigators. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment. Pharmacol. Ther. 2004; 20 (11–12): 1317–22. https://doi.org/10.1111/j.1365–2036.2004.02284.xLong Y., Du L., Kim J. J., Chen B., Zhu Y., Zhang Y. et al. MLCK-mediated intestinal permeability promotes immune activation and visceral hypersensitivity in PI–IBS mice. Neurogastroenterol. Motil. 2018; 30 (9): e13348. https://doi.org/doi:10.1111/nmo.13348Long Y., Du L., Kim J. J., Chen B., Zhu Y., Zhang Y. et al. MLCK-mediated intestinal permeability promotes immune activation and visceral hypersensitivity in PI–IBS mice. Neurogastroenterol. Motil. 2018; 30 (9): e13348. https://doi.org/doi:10.1111/nmo.13348Du L., Long Y, Kim JJ, Chen B, Zhu Y, Dai N. Protease Activated Receptor-2 Induces Immune Activation and Visceral Hypersensitivity in Post-infectious Irritable Bowel Syndrome Mice. Dig Dis Sci. 2019; 64 (3): 729–739. https://doi.org/10.1007/s10620–018–5367-yDu L., Long Y, Kim JJ, Chen B, Zhu Y, Dai N. Protease Activated Receptor-2 Induces Immune Activation and Visceral Hypersensitivity in Post-infectious Irritable Bowel Syndrome Mice. Dig Dis Sci. 2019; 64 (3): 729–739. https://doi.org/10.1007/s10620–018–5367-yWang L. H., Fang X. C., Pan G. Z. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut. 2004; 53 (8): 1096–101. https://doi.org/10.1136/gut.2003.021154Wang L. H., Fang X. C., Pan G. Z. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut. 2004; 53 (8): 1096–101. https://doi.org/10.1136/gut.2003.021154Cremon C., Gargano L., Morselli-Labate A.M., Santini D., Cogliandro R. F., De Giorgio R. et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am. J. Gastroenterol. 2009; 104 (2): 392–400. https://doi.org/10.1038/ajg.2008.94Cremon C., Gargano L., Morselli-Labate A.M., Santini D., Cogliandro R. F., De Giorgio R. et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am. J. Gastroenterol. 2009; 104 (2): 392–400. https://doi.org/10.1038/ajg.2008.94Spiller R. C., Jenkins D., Thornley J. P., Hebden J. M., Wright T., Skinner M., Neal K. R. In-creased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000; 47 (6): 804–11. https://doi.org/10.1136/gut.47.6.804Spiller R. C., Jenkins D., Thornley J. P., Hebden J. M., Wright T., Skinner M., Neal K. R. In-creased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000; 47 (6): 804–11. https://doi.org/10.1136/gut.47.6.804Kim H. S., Lim J. H., Park H., Lee S. I. Increased immunoendocrine cells in intestinal mucosa of postinfectious irritable bowel syndrome patients 3 years after acute Shigella infection – an observation in a small case control study. Yonsei Med. J. 2010; 51 (1): 45–51. https://doi.org/10.3349/ymj.2010.51.1.45Kim H. S., Lim J. H., Park H., Lee S. I. Increased immunoendocrine cells in intestinal mu-cosa of postinfectious irritable bowel syndrome patients 3 years after acute Shigella infection – an observation in a small case control study. Yonsei Med. J. 2010; 51 (1): 45–51. https://doi.org/10.3349/ymj.2010.51.1.45Sundin J., Rangel I., Fuentes S., Heikampde Jong I., Hultgren-Hörnquist E., de Vos W. M., Brummer R. J. Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress. Aliment. Pharmacol. Ther. 2015; 41 (4): 342–51. https://doi. org/10.1111/apt.13055Sundin J., Rangel I., Fuentes S., Heikamp-de Jong I., Hultgren-Hörnquist E., de Vos W. M., Brummer R. J. Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress. Aliment. Pharmacol. Ther. 2015; 41 (4): 342–51. https://doi.org/10.1111/apt.13055Dong L. W., Sun X. N., Ma Z. C., Fu J., Liu F. J. et al. Increased Vδ1γδT cells predominantly contributed to IL-17 production in the development of adult human post-infectious irritable bowel syndrome. BMC Gastroenterol. 2021; 21 (1): 271. https://doi.org/10.1186/s12876–021–01722–8Dong L. W., Sun X. N., Ma Z. C., Fu J., Liu F. J. et al. Increased Vδ1γδT cells predominantly contributed to IL-17 production in the development of adult human post-infectious irritable bowel syndrome. BMC Gastroenterol. 2021; 21 (1): 271. https://doi.org/10.1186/s12876–021–01722–8Born W. K., Jin N., Aydintug M. K., Wands J. M., French J. D. et al. gamma-delta T lymphocytes-selectable cells within the innate system? J Clin Immunol. 2007; 27 (2): 133–44. https://doi.org/10.1007/s10875–007–9077-zBorn W. K., Jin N., Aydintug M. K., Wands J. M., French J. D. et al. gamma-delta T lymphocytes-selectable cells within the innate system? J Clin Immunol. 2007; 27 (2): 133–44. https://doi.org/10.1007/s10875–007–9077-zBorn W. K., Reardon C. L., O'Brien R. L. The function of gammadelta T cells in innate im-munity. Curr. Opin. Immunol. 2006; 18 (1): 31–8. https://doi.org/10.1016/j.coi.2005.11.007Born W. K., Reardon C. L., O'Brien R. L. The function of gammadelta T cells in innate im-munity. Curr. Opin. Immunol. 2006; 18 (1): 31–8. https://doi.org/10.1016/j.coi.2005.11.007Nizhegorodova D. B., Zafranskaya M. M. γδТ-lymphocytes: general characteristics, subpopulation profile, biological role, and functional features. Med. Immunol. 2009; 11 (3–3): 115–130.Нижегородова Д. Б., Зафранская М. М. γδТ-лимфоциты: общая характеристика, субпопуляционный состав, биологическая роль и функциональные особенности. Медицинская иммунология. 2009; 11 (3–3): 115–130.Rajilić-Stojanović M., de Vos W. M. The first 1000 cultured species of the human gastrointestinal microbiota. FEMS Microbiol Rev. 2014; 38 (5): 996–1047. https://doi.org/10.1111/1574–6976.12075Rajilić-Stojanović M., de Vos W. M. The first 1000 cultured species of the human gastrointestinal microbiota. FEMS Microbiol Rev. 2014; 38 (5): 996–1047. https://doi.org/10.1111/1574–6976.12075Spiller R. Significance of Postinfectious Irritable Bowel Syndrome? Gastroenterology. 2018: S 0016–5085 (18) 35282-X. https://doi.org/10.1053/j.gastro.2018.11.034Spiller R. Significance of Postinfectious Irritable Bowel Syndrome? Gastroenterology. 2018: S 0016–5085 (18) 35282-X. https://doi.org/10.1053/j.gastro.2018.11.034Ha S., Jin B., Clemmensen B., Park P., Mahboob S., Gladwill V. et al. Serotonin is elevated in COVID-19-associated diarrhoea. Gut. 2021; 70 (10): 2015–2017. https://doi.org/10.1136/gutjnl-2020–323542Ha S., Jin B., Clemmensen B., Park P., Mahboob S., Gladwill V. et al. Serotonin is elevated in COVID-19-associated diarrhoea. Gut. 2021; 70 (10): 2015–2017. https://doi.org/10.1136/gutjnl-2020–323542Ernstsen L., Havnen A. Mental health and sleep disturbances in physically active adults during the COVID-19 lockdown in Norway: does change in physical activity level matter? Sleep Med. 2021; 77: 309–312. https://doi.org/10.1016/j.sleep.2020.08.030Ernstsen L., Havnen A. Mental health and sleep disturbances in physically active adults during the COVID-19 lockdown in Norway: does change in physical activity level matter? Sleep Med. 2021; 77: 309–312. https://doi.org/10.1016/j.sleep.2020.08.030Di Renzo L., Gualtieri P., Pivari F., Soldati L., Attinà A., Cinelli G. et al. Eating habits and lifestyle changes during COVID 19 lockdown: an Italian survey. J. Transl. Med. 2020; 18 (1): 229. https://doi.org/10.1186/s12967–020–02399–5Di Renzo L., Gualtieri P., Pivari F., Soldati L., Attinà A., Cinelli G. et al. Eating habits and lifestyle changes during COVID 19 lockdown: an Italian survey. J. Transl. Med. 2020; 18 (1): 229. https://doi.org/10.1186/s12967–020–02399–5Lima C. K.T., Carvalho P. M.M., Lima I. A.A.S., Nunes J. V.A.O., Saraiva J. S., de Souza R. I. et al. The emotional impact of Coronavirus 2019-nCoV (new Coronavirus disease). Psychiatry Res. 2020; 287: 112915. https://doi.org/10.1016/j.psychres.2020.112915Lima C. K.T., Carvalho P. M.M., Lima I. A.A.S., Nunes J. V.A.O., Saraiva J. S., de Souza R. I. et al. The emotional impact of Coronavirus 2019-nCoV (new Coronavirus disease). Psychiatry Res. 2020; 287: 112915. https://doi.org/10.1016/j.psychres.2020.112915Sidor A., Rzymski P. Dietary Choices and Habits during COVID-19 Lockdown: Experience from Poland. Nutrients. 2020; 12 (6): 1657. https://doi.org/10.3390/nu12061657Sidor A., Rzymski P. Dietary Choices and Habits during COVID-19 Lockdown: Experience from Poland. Nutrients. 2020; 12 (6): 1657. https://doi.org/10.3390/nu12061657Batlle-Bayer L., Aldaco R., Bala A., Puig R., Laso J., Margallo M. et al. Environmental and nutritional impacts of dietary changes in Spain during the COVID-19 lockdown. Sci. Total. Environ. 2020; 748: 141410. https://doi.org/10.1016/j.scitotenv.2020.141410Batlle-Bayer L., Aldaco R., Bala A., Puig R., Laso J., Margallo M. et al. Environmental and nutritional impacts of dietary changes in Spain during the COVID-19 lockdown. Sci. Total. Environ. 2020; 748: 141410. https://doi.org/10.1016/j.scitotenv.2020.141410Horikawa C., Murayama N., Kojima Y., Tanaka H., Morisaki N. Changes in Selected Food Groups Consumption and Quality of Meals in Japanese School Children during the COVID-19 Pandemic. Nutrients. 2021; 13 (8): 2743. https://doi.org/10.3390/nu13082743Horikawa C., Murayama N., Kojima Y., Tanaka H., Morisaki N. Changes in Selected Food Groups Consumption and Quality of Meals in Japanese School Children during the COVID-19 Pandemic. Nutrients. 2021; 13 (8): 2743. https://doi.org/10.3390/nu13082743Halmos E. P., Power V. A., Shepherd S. J., Gibson P. R., Muir J. G. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014; 146(1): 67–75. e5. https://doi.org/10.1016/10.1053/j.gastro.2013.09.046Halmos E. P., Power V. A., Shepherd S. J., Gibson P. R., Muir J. G. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014; 146(1): 67–75. e5. https://doi.org/10.1016/10.1053/j.gastro.2013.09.046Chang F. Y., Lu C. L., Chen C. Y., Luo J. C. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2007; 22 (12): 2266–72. https://doi.org/10.1111/j.1440–1746.2007.04895.xChang F. Y., Lu C. L., Chen C. Y., Luo J. C. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2007; 22 (12): 2266–72. https://doi.org/10.1111/j.1440–1746.2007.04895.xDrossman D. A., Tack J., Ford A. C., Szigethy E., Törnblom H., Van Oudenhove L. Neuro-modulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report. Gastroenterology. 2018; 154 (4): 1140–1171. e1. https://doi.org/10.1053/j.gastro.2017.11.279Drossman D. A., Tack J., Ford A. C., Szigethy E., Törnblom H., Van Oudenhove L. Neuro-modulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report. Gastroenterology. 2018; 154 (4): 1140–1171. e1. https://doi.org/10.1053/j.gastro.2017.11.279Ford A. C., Brandt L. J., Young C., Chey W. D., Foxx-Orenstein A.E., Moayyedi P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am. J. Gastroenterol. 2009; 104 (7): 1831–43; quiz 1844. https://doi.org/10.1038/ajg.2009.223Ford A. C., Brandt L. J., Young C., Chey W. D., Foxx-Orenstein A.E., Moayyedi P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am. J. Gastroenterol. 2009; 104 (7): 1831–43; quiz 1844. https://doi.org/10.1038/ajg.2009.223Ford A. C., Quigley E. M., Lacy B. E., Lembo A. J., Saito Y. A., Schiller L. R. et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am. J. Gastroenterol. 2014; 109 (10): 1547–61; quiz 1546, 1562. https://doi.org/10.1038/ajg.2014.202Ford A. C., Quigley E. M., Lacy B. E., Lembo A. J., Saito Y. A., Schiller L. R. et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am. J. Gastroenterol. 2014; 109 (10): 1547–61; quiz 1546, 1562. https://doi.org/10.1038/ajg.2014.202Parker E. A., Roy T., D’Adamo C.R., Wieland L. S. Probiotics and gastrointestinal con-ditions: An overview of evidence from the Cochrane Collaboration. Nutrition. 2018; 45 (2018): 125–134. https://doi.org/10.1016/j.nut.2017.06Parker E. A., Roy T., D’Adamo C.R., Wieland L. S. Probiotics and gastrointestinal con-ditions: An overview of evidence from the Cochrane Collaboration. Nutrition. 2018; 45 (2018): 125–134. https://doi.org/10.1016/j.nut.2017.06Li B., Liang L. Deng H., Guo J., Shu H., Zhang L. Efficacy and safety of probiotics in irritable bowel syndrome: a systematic review and meta-analysis. Front Pharmacol. 2020; 11: 332. https://doi.org/10.3389/fphar.2020.00332Li B., Liang L. Deng H., Guo J., Shu H., Zhang L. Efficacy and safety of probiotics in irritable bowel syndrome: a systematic review and meta-analysis. Front Pharmacol. 2020; 11: 332. https://doi.org/10.3389/fphar.2020.00332Global Practice Guidelines of the World Gastroenterology Organization. Probiotics and prebiotics. https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-russian-2017.pdfГлобальные практические рекомендации Всемирной гастроэнтерологической организации. Пробиотики и пребиотики. https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-russian-2017.pdfConnel M., Shin A., James-Stevenson T., Xu H., Imperiale T. F., Herron J. Systematic review and meta-analysis: efficacy of patented probiotic, VSL#3, in irritable bowel syn-drome. Neurogastroenterol. Motil. 2018; 30 (12): e13427. https://doi.org/10.1111/nmoConnel M., Shin A., James-Stevenson T., Xu H., Imperiale T. F., Herron J. Systematic review and meta-analysis: efficacy of patented probiotic, VSL#3, in irritable bowel syn-drome. Neurogastroenterol. Motil. 2018; 30 (12): e13427. https://doi.org/10.1111/nmoChong P. P., Chin V. K., Looi C. Y., Wong W. F., Madhavan P., Yong V. C. The Micro-biome and Irritable Bowel Syndrome – A Review on the Pathophysiology, Current Research and Future Therapy. Front. Microbiol. 2019; 10: 1136. https://doi.org/10.3389/fmicb.2019.0113Chong P. P., Chin V. K., Looi C. Y., Wong W. F., Madhavan P., Yong V. C. The Micro-biome and Irritable Bowel Syndrome – A Review on the Pathophysiology, Current Research and Future Therapy. Front. Microbiol. 2019; 10: 1136. https://doi.org/10.3389/fmicb.2019.0113Zang R., Gomez Castro M. F., McCune B.T., Zeng Q., Rothlauf P. W. et al. TMPRSS 2 and TMPRSS 4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci. Immunol. 2020; 5 (47): eabc3582. https://doi.org/10.1126/sciimmunol.abc3582Zang R., Gomez Castro M. F., McCune B.T., Zeng Q., Rothlauf P. W. et al. TMPRSS 2 and TMPRSS 4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci. Immunol. 2020; 5 (47): eabc3582. https://doi.org/10.1126/sciimmunol.abc3582Turner R. B., Woodfolk J. A., Borish L., Steinke J. W., Patrie J. T., Muehling L. M. et al. Effect of probiotic on innate inflammatory response and viral shedding in experimental rhinovirus infection – a randomised controlled trial. Beneficial Microbes. 2017; 8 (2): 207–215. https://doi.org/10.3920/BM2016.0160Turner R. B., Woodfolk J. A., Borish L., Steinke J. W., Patrie J. T., Muehling L. M. et al. Effect of probiotic on innate inflammatory response and viral shedding in experimental rhinovirus infection – a randomised controlled trial. Beneficial Microbes. 2017; 8 (2): 207–215. https://doi.org/10.3920/BM2016.0160Szajewska H., Kołodziej M. Systematic review with meta-analysis: Lactobacillus rham-nosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Aliment. Pharmacol. Ther. 2015; 42 (10): 1149–1157. https://doi.org/10.1111/apt.13404Szajewska H., Kołodziej M. Systematic review with meta-analysis: Lactobacillus rham-nosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Aliment. Pharmacol. Ther. 2015; 42 (10): 1149–1157. https://doi.org/10.1111/apt.13404Szajewska H., Kołodziej M. Systematic review with meta-analysis: Lactobacillus rham-nosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Aliment. Pharmacol. Ther. 2015; 42 (10): 1149–1157. https://doi.org/10.1111/apt.13404

The authors declare that there are no conflicts of interest present.